<DOC>
	<DOCNO>NCT01344226</DOCNO>
	<brief_summary>Investigate intraocular pressure ( pressure inside eye ) patient treat Lotemax undergo cataract surgery .</brief_summary>
	<brief_title>Clinical Outcomes Evaluation Lotemax 0.5 % Treatment Ocular Inflammation Associated With Cataract Surgery</brief_title>
	<detailed_description>This single-center study evaluate clinical outcome Lotemax 0.5 % treatment Ocular inflammation associate cataract surgery . Subjects screen one 21 day prior initiation dose test article . Subjects sign inform consent document meet inclusion/exclusion criterion eligible participate study . Subjects instill one drop Lotemax study ( operative ) eye QID maximum 22 day . Dosing test article begin day surgery 21 day surgery . Subjects see evaluation Days 1 , 7±1 , 21 ± 2 follow surgery . Subjects see follow-up visit Day 42 ± 3 follow surgery , 21 day last dose test article . In addition test article regimen , subject receive Vigamox TID 3 day prior surgery . Patients receive one drop Timoptic XE 0.5 % , Zymaxid day surgery . Postoperatively , patient receive Vigamox TID ten day Bromday QD 3 week .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pseudophakia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male Female 18 year age schedule unilateral cataract surgery ( phacoemulsification extracapsular ) posterior chamber intraocular lens implantation . 2 . Agree ocular surgery study fellow eye duration study . 3 . Have BCVA 20/200 good either eye . 4 . Willing/able return require study visit . 5 . Willing/able follow instruction study investigator staff . 6 . Able selfadminister test article ( caregiver available instill dose test article ) . 7 . If woman capable become pregnant , agree urine pregnancy test ( must negative ) agree use medically acceptable form birth control study least one week prior completion study . 8 . Have read , understood , sign informed consent document approve Sterling Institutional Review Board . 9 . Have IOP ≥ 5mmHg ≤ 22mmHg , ( study eye ) without antiglaucoma therapy preoperative screening visit ( &gt; 22mmHg , adjust follow pachymetry ) . 1 . Have know hypersensitivity Lotemax component test article ( include `` procedural '' medication anesthetic and/or fluorescein drop , dilate drop , etc. ) . 2 . Have know hypersensitivity nonsteroidal steroidal antiinflammatory drug ( NSAIDs ) . 3 . Have intraocular inflammation ( i.e . cell flare anterior chamber measure slit lamp exam ) study eye screen visit . 4 . Have know blood dyscrasia bone marrow suppression , diagnosis uncontrolled/unstable peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , uncontrolled/unstable pulmonary , cardiac , vascular , autoimmune , hepatic , renal , central nervous system disease . 5 . Have use ocular , topical , systemic steroid within 14 day depot steroid 30 day prior initiation dose test article throughout duration study . Note : use opioid surgery ( e.g. , fentanyl ) allow . 6 . Have uncontrolled glaucoma IOP &gt; /= 27mmHg . 7 . Have active corneal pathology note study eye screen visit . Active corneal pathology define corneal pathology nonstable , great mild , compromise assessment safety efficacy treatment . 8 . Are pregnant nursing . 9 . Have participate study investigational drug device within 30 day prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>steroid responder</keyword>
</DOC>